Article Details

Emalex Closes $250M Series D to Fund Phase III Trial in Tourette Syndrome | BioSpace

Retrieved on: 2022-11-03 15:10:23

Tags for this article:

Click the tags to see associated articles and topics

Emalex Closes $250M Series D to Fund Phase III Trial in Tourette Syndrome | BioSpace. View article details on hiswai:

Excerpt

In a statement, Emalex founder and Paragon CEO Jeff Aronin said that the Chicago-based neuroscience biotech was created specifically to address ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up